title: Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients.
abstract: Intravenous immunoglobulin (IVIG) replacement has been shown to decrease the risk of post-transplant infections secondary to hypogammaglobulinemia, however the use of subcutaneous immunoglobulin (SCIG) in this population has not been reported. A retrospective analysis of the efficacy and tolerability of subcutaneous immunoglobulin replacement on 10 lung-transplant recipients was performed. All 10 patients demonstrated an increase in IgG levels at three months that was sustained at 6-12 months with SCIG replacement therapy, with the majority (70%) tolerating infusion without complications. The results of this study suggest that subcutaneous IgG replacement therapy is a well tolerated alternative to IVIG.
authors.affiliation: Department of Medicine, University of Pittsburgh Medical Center, USA.
authors.forename: T
authors.initials: T
authors.lastname: Shankar
authors.forename: J
authors.initials: J
authors.lastname: Gribowicz
authors.forename: M
authors.initials: M
authors.lastname: Crespo
authors.forename: F P
authors.initials: FP
authors.lastname: Silveira
authors.forename: J
authors.initials: J
authors.lastname: Pilewski
authors.forename: A A
authors.initials: AA
authors.lastname: Petrov
mesh_terms: D000368:Aged; D057286:Electronic Health Records; D005260:Female; D006801:Humans; D017099:IgG Deficiency / Q000097:blood / Q000517:prevention & control*; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007136:Immunoglobulins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D055104:Infusions, Subcutaneous; D016040:Lung Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: C558471:Hizentra; D007074:Immunoglobulin G; D007136:Immunoglobulins; D007155:Immunologic Factors; C510539:Vivaglobin